Hepatitis A Vaccine
It is a sterile suspension containing formaldehyde-inactivated hepatitis A virus (HM 175 hepatitis A virus strain) adsorbed onto aluminium hydroxide. The virus is propagated in MRC5 human diploid cells. An adult dose is standardised to ensure a viral antigen content of not less than 720 ELISA units of viral antigens, in a 1 ml dose volume. A paediatric dose is standardised to ensure a viral antigen content of not less than 360 ELISA units of viral antigens in a 0.5 ml dose volume.Active immunisation against hepatitis A virus infection.
Adult: 1 ml/not less than 720 ELISA units. Paediatrics: 0.5 ml/not less than 360 ELISA units. Immunisation schedule: First dose at elected date and second one month later. If necessary, second dose may be administered a minimum of two weeks following the first dose. Booster dose is recommended at any time between 6 & 12 months after initiation of primary course.
Acute severe febrile illness.
Administer with caution to subjects with thrombocytopenia or a bleeding disorder. Should not be administered intravenously.
Mild headache, malaise, fatigue, fever, nausea and loss of appetite.
Brand Name | Manufactured by |
---|---|
HAVRIX | GLAXO-SMITHKLINE |